Wednesday, September 5, 2018

Benign Prostatic Hyperplasia Therapeutics Market Emerging Technologies, Regional Trends, Competitive Landscape, Regional Analysis & Forecasts to 2019

Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy, is a urological disorder that involves proliferation of the cellular components of the prostrate. BPH is the most common form of neoplasm in men. BPH results in the formation of large nodes and nodules in the periurethral region of the prostate. The significantly large nodules compresses the urethral canal that causes to partial or complete urinary tract obstruction which inhibits the normal flow of urine. Obstruction in the urinary tract further leads to complications such as urinary retention, urinary tract infections and urinary hesitancy.

Report Overview @ https://www.transparencymarketresearch.com/bph-therapeutics-market.html

Geographically, North America is the leading market due to high prevalence rate of benign prostatic hyperplasia and lower urinary tract symptoms (LUTS). Various studies reports that 90% of men in the U.S., aged between 45 and 80 years suffer from some type of LUTS and approximately 14 million men in the U.S. have symptoms of BPH. Asia-Pacific is also expected to witness a significant growth due to the rise in various urological disorders and complications. However, BPH tends to be more progressive in African-American men owing to the presence of high testosterone level in their body.
Rise in geriatric population is expected to be one of the major driver that might drive the market. Additionally, increased awareness for prostate cancer and other urological disorders, are also expected to fuel the growth of the global BPH therapeutics market. However, high adoption rate of minimally invasive surgeries such as transurethral microwave thermotherapy (TUMT), laparoscopic prostatectomy and transurethral needle ablation (TUNA) might impede the growth of the BPH therapeutics market.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1872

Some of the key players in the benign prostatic hyperplasia (BPH) therapeutics Market are AEternaZentaris Inc., Astellas Pharma Inc., Eli Lilly and Company, EndoCeutics, Inc., IntelGenx Technologies Corp., Ipsen S.A., Nymox Pharmaceutical Corporation, Protox Therapeutics Inc. and Quest PharmaTech Inc.
This research report analyzes this market depending on its market segments, major geographies, and current market trends.

Popular Research Reports by TMR:

Operating Room Equipment Market: http://www.prnewswire.co.uk/news-releases/operating-room-equipment-market-to-generate-us428733-million-revenue-by-2026-says-tmr-691005331.html

Viral Inactivation Market: https://globenewswire.com/news-release/2018/08/24/1556475/0/en/Viral-Inactivation-Market-is-Projected-to-Surpass-US-5-736-bn-by-2025-Says-TMR.html

No comments:

Post a Comment